Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 

CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies Australia Pty Ltd has initiated independent analyst coverage on the Company. […] Download PDF

Download PDF
 
 

The Value in the Vines Investor Conference Presentation is available to download.

Download PDF
 
 

  Appendix 4G and Corporate Governance Statement is available to download.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual Report 2020

CLINUVEL’s Annual Report for the year ended 30 June 2020 is available to download here.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on Wednesday, 11 November 2020 at 06.00pm (Melbourne time). To comply with COVID19 requirements set out in Government restrictions on travel and public gatherings, the AGM will be held as a virtual meeting. The Company will rely on technology to facilitate shareholder engagement during […]

Download PDF
 
 
Wednesday, 07 October 2020

SCIENTIFIC COMMUNIQUÉ VI

Despite government campaigns to curb increases, current statistics show the rate of skin cancer is escalating, particularly in regions with predominantly fair-skinned populations. Skin cancer diagnoses have increased considerably over the last five decades, at a rate of 4% per annum. Approximately 5.3 million individuals are diagnosed with a skin cancer in the USA annually. […]

Download PDF
 
 
Tuesday, 06 October 2020

CLINUVEL News & Facts site live

Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL News & Facts site gives an opportunity to explore and discuss the people, science and ideas that underpin CLINUVEL. Read more about the concept here.

Download PDF
 
 
Monday, 28 September 2020

Kommuniqué V, 2020

Kommuniqué V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Newsletter V

CLINUVEL Newsletter V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Confirms AGM Date

CLINUVEL Confirms AGM Date

Download PDF
 
 
Wednesday, 16 September 2020

Change of Director’s Interest Notice

Appendix 3Y – Change of Director’s Interest Notice is available to download as PDF

Download PDF
 
 

First patient dosed in SCENESSE® DNA Repair Program Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet (UV) radiation. Following the treatment of a patient suffering from xeroderma pigmentosum (XP), a disease characterised […]

www.clinuvel.com.

Download PDF

 
 

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced that the first patient diagnosed with xeroderma pigmentosum (XP-C) has received SCENESSE® (afamelanotide 16mg).1 The Special Access Program of one patient is part of CLINUVEL’s DNA Repair Program. CLINUVEL is evaluating SCENESSE® in a staged clinical program to confirm the drug’s ability to […]

www.clinuvel.com.

Download PDF

 
 

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to protect skin from light (photoprotection) and shown to repair DNA damage. Since photoprotection and regeneration are necessary to reduce the risk of skin […]

www.clinuvel.com.

Download PDF

 
 

CLINUVEL progresses innovative DNA Repair Program Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to […]

www.clinuvel.com.

Download PDF

 
Friday, 08 May 2020

Chair Letter to Shareholders

Fellow shareholders,In my March letter I wished all good health during uncertain times. It is now clear the extent of damage COVID-19 has caused and will cause for many years in the future. I want …

Download PDF
 

Innovative drug launched for rare, isolating, “light intolerance” disorder Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or burning reactions from exposure to light, are welcoming an …

www.clinuvel.com

 

1 SCENESSE® (afamelanotide 16mg) is approved in the European Union as an orphan medicinal product for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). SCENESSE® is approved in the USA to increase pain free light exposure in adult EPP patients with a history of phototoxicity. Information on the product, including the approved prescribing information, can be found on CLINUVEL’s website at www.clinuvel.com.

2 Biolcati et al. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British Journal of Dermatology. 172(6), 1601–1612. Langendonk et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. The New England Journal of Medicine. 373(1), 48–59. Wensink et al. (2020). Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatology. EPub 18 March 2020.

Download PDF

 

CLINUVEL PHARMACEUTICALS LTD today announced that US insurance companies have agreed to reimburse SCENESSE® (afamelanotide) for patients diagnosed with erythropoietic protoporphyria (EPP).1SCENESSE® was approved by the US Food and Drug Administration (FDA) in October 2019 …

www.clinuvel.com.

2 Further details and terms and conditions are available from www.scenesse.com. This site is intended for US residents only.

Download PDF

 
Monday, 23 March 2020

CLINUVEL Kommuniqué II

Sehr geehrte Aktionäre, liebe Freunde,im Laufe des Jahres haben wir einen deutlichen Rückgang der globalen Aktienmärkte erlebt, der den Wertverlust von CLINUVEL noch verstärkt hat. Obwohl dies für viele unserer Aktionäre, einschließlich der Mitarbeiter, die …

Download PDF
 
Thursday, 19 March 2020

CLINUVEL Newsletter

Dear shareholders, friends,As the year unfolds, we have witnessed the significant downturn of global stock markets which has compounded the decline of CLINUVEL’s value. While regretful and painful for many of our shareholders, including staff …

Download PDF
 
Thursday, 12 March 2020

Chair Letter to Shareholders

Fellow shareholders,Let me start a first welcome letter by wishing you a successful and great year ahead without health issues, pertinent at the time that Corona virus is taking over the world news.Since appointed in …

Download PDF
 
Wednesday, 29 January 2020

CLINUVEL Kommuniqué I

Sehr geehrte Aktionärinnen und Aktionäre, liebe FreundeIm Namen des CLINUVEL-Ausschusses wünsche ich Ihnen allen ein gutes neues Jahr in der Hoffnung, dass es Ihnen Gesundheit und Wohlstand verleiht. Wir bedanken uns vielmals bei Stan McLiesh, …

Download PDF
 
Thursday, 16 January 2020

CLINUVEL Newsletter

Dear shareholders, friendsOn behalf of the CLINUVEL Board, I wish you all a good new year in the hope that it confers you with good health and prosperity, in that particular sequence. We thank and …

Download PDF
 
Thursday, 05 December 2019

Appendix 3B

 New issue announcement, application for quotation of additional securities and agreement. 

Download PDF
 
Monday, 02 December 2019

CEO Letter

Dear shareholders, On 8 October 2019, CLINUVEL obtained its first and historic US Food and Drug Administration (FDA) approval, some 39 years since the afamelanotide technology was first discovered in a university laboratory. On this day …

Download PDF